Literature DB >> 11211312

Interferon-gamma stimulates the expression of CX3CL1/fractalkine in cultured human endothelial cells.

T Imaizumi1, T Matsumiya, K Fujimoto, K Okamoto, X Cui, U Ohtaki, K Satoh.   

Abstract

CX3CL1/Fractalkine, a CX3C chemokine, is a potent agonist for the chemotaxis and adhesion of monocytes and lymphocytes. It was first identified as a membrane protein in endothelial cells activated with IL-1 or TNF-alpha. We have found the enhanced expression of fractalkine in human umbilical vein endothelial cells stimulated with interferon-gamma (IFN-gamma). Pretreatment of the cells with cycloheximide did not inhibit the expression of fractalkine mRNA. The majority of fractalkine protein was found in the cell lysate, and an antibody-blocking experiment disclosed that fractalkine contributes to the adhesion of mononuclear cells to endothelial monolayers stimulated with IFN-gamma. Vascular endothelial cells produce fractalkine in response to IFN-gamma, and this may play an important role in immune responses by eliciting a traffic of mononuclear cells through the vascular wall.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11211312     DOI: 10.1620/tjem.192.127

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  14 in total

1.  Functional adhesiveness of the CX3CL1 chemokine requires its aggregation. Role of the transmembrane domain.

Authors:  Patricia Hermand; Frédéric Pincet; Stéphanie Carvalho; Hervé Ansanay; Eric Trinquet; Mehdi Daoudi; Christophe Combadière; Philippe Deterre
Journal:  J Biol Chem       Date:  2008-08-25       Impact factor: 5.157

Review 2.  Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia.

Authors:  R Cotter; C Williams; L Ryan; David Erichsen; A Lopez; H Peng; J Zheng
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

3.  CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin.

Authors:  Dan Sunnemark; Sana Eltayeb; Maria Nilsson; Erik Wallström; Hans Lassmann; Tomas Olsson; Anna-Lena Berg; Anders Ericsson-Dahlstrand
Journal:  J Neuroinflammation       Date:  2005-07-29       Impact factor: 8.322

Review 4.  The pathogenic role of angiogenesis in rheumatoid arthritis.

Authors:  Hatem A Elshabrawy; Zhenlong Chen; Michael V Volin; Shalini Ravella; Shanti Virupannavar; Shiva Shahrara
Journal:  Angiogenesis       Date:  2015-07-22       Impact factor: 9.596

5.  Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases.

Authors:  Jianliang Zhang; Jawaharlal M Patel
Journal:  Int J Clin Exp Med       Date:  2010-08-10

6.  Heparin inhibits IFN-gamma-induced fractalkine/CX3CL1 expression in human endothelial cells.

Authors:  Masaharu Hatakeyama; Tadaatsu Imaizumi; Wakako Tamo; Koji Yamashita; Hidemi Yoshida; Ikuo Fukuda; Kei Satoh
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

Review 7.  Origin and production of inflammatory perivascular macrophages in pulmonary hypertension.

Authors:  Jonathan Florentin; Partha Dutta
Journal:  Cytokine       Date:  2017-08-30       Impact factor: 3.861

8.  IL-17A Contributes to the Pathogenesis of Endometriosis by Triggering Proinflammatory Cytokines and Angiogenic Growth Factors.

Authors:  Soo Hyun Ahn; Andrew K Edwards; Sukhbir S Singh; Steven L Young; Bruce A Lessey; Chandrakant Tayade
Journal:  J Immunol       Date:  2015-08-10       Impact factor: 5.422

Review 9.  Endothelial cells in allograft rejection.

Authors:  Rafia S Al-Lamki; John R Bradley; Jordan S Pober
Journal:  Transplantation       Date:  2008-11-27       Impact factor: 4.939

10.  Altered expression of fractalkine in HIV-1-infected astrocytes and consequences for the virus-related neurotoxicity.

Authors:  Vincent Sénécal; Corinne Barat; Marie-Thérèse Gagnon; François Vanasse; Mathieu Leboeuf; David Gosselin; Michel J Tremblay
Journal:  J Neurovirol       Date:  2021-03-01       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.